Technical Analysis for BIIB - Biogen Idec Inc.

Grade Last Price % Change Price Change
grade D 291.87 -2.51% -7.51
BIIB closed down 2.51 percent on Friday, February 16, 2018, on 2.05 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
4 Watchers
Track This Stock
Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical BIIB trend table...

Date Alert Name Type % Chg
Feb 16 180 Bearish Setup Bearish Swing Setup 0.00%
Feb 16 Boomer Sell Setup Bearish Swing Setup 0.00%
Feb 16 Inside Day Range Contraction 0.00%
Feb 16 Wide Bands Range Expansion 0.00%
Feb 16 Oversold Stochastic Weakness 0.00%
Feb 15 Jack-in-the-Box Bearish Bearish Swing Setup -2.51%
Feb 15 Calm After Storm Range Contraction -2.51%
Feb 15 Lower Bollinger Band Walk Weakness -2.51%
Feb 15 Multiple of Ten Bearish Other -2.51%
Feb 15 Inside Day Range Contraction -2.51%

Older signals for BIIB ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Its marketed products include AVONEX for the treatment of relapsing multiple sclerosis (MS); TYSABRI to treat relapsing MS; RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin's lymphoma (NHL); FUMADERM for the treatment of severe plaque psoriasis in adult patients; and FAMPYRA, an oral compound for the improvement of walking in adult patients with MS with walking disability. The company's products that completed Phase III clinical trials comprise TECFIDERA (BG-12) for MS; Peginterferon beta-1a to prolong the effects and reduce the dosing frequency of interferon beta-1a; and long-lasting Factor VIII and IX product candidates for the treatment of hemophilia. Its products under Phase III clinical trials consist of Daclizumab, a monoclonal antibody in relapsing MS; TYSABRI for secondary progressive MS; and GA101, a monoclonal antibody for chronic lymphocytic leukemia and NHL. The company's Phase II clinical trial products include Anti-LINGO for optic neuritis; STX-100 for idiopathic pulmonary fibrosis; and ANTI-TWAEK for lupus nephritis. The company's Phase I clinical trial products comprise Anti-LINGO for MS; BIIB037 for Alzheimer's disease; Neublastin for neuropathic pain; and Anti-CD40 Ligand for general lupus, as well as Phase 1b/2a clinical trial product includes ISIS-SMNRx for spinal muscular atrophy. It has collaboration agreements with Genentech, Inc.; Elan Pharma International, Ltd; Acorda Therapeutics, Inc.; Portola Pharmaceuticals, Inc.; and Swedish Orphan Biovitrum AB. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Weston, Massachusetts.
Is BIIB a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 370.57
52 Week Low 244.28
Average Volume 1,370,164
200-Day Moving Average 302.8442
50-Day Moving Average 331.0568
20-Day Moving Average 332.4415
10-Day Moving Average 313.758
Average True Range 11.3889
ADX 32.61
+DI 10.99
-DI 38.43
Chandelier Exit (Long, 3 ATRs ) 336.4033
Chandelier Exit (Short, 3 ATRs ) 322.1667
Upper Bollinger Band 375.4498
Lower Bollinger Band 289.4332
Percent B (%b) 0.03
BandWidth 25.874206
MACD Line -10.028
MACD Signal Line -4.421
MACD Histogram -5.607
Fundamentals Value
Market Cap 61.71 Billion
Num Shares 211 Million
EPS 15.24
Price-to-Earnings (P/E) Ratio 19.15
Price-to-Sales 5.55
Price-to-Book 5.61
PEG Ratio 2.22
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 303.30
Resistance 3 (R3) 304.24 301.37 301.40
Resistance 2 (R2) 301.37 298.46 300.90 300.76
Resistance 1 (R1) 296.62 296.66 295.19 295.68 300.12
Pivot Point 293.75 293.75 293.03 293.28 293.75
Support 1 (S1) 289.00 290.84 287.57 288.06 283.62
Support 2 (S2) 286.13 289.04 285.66 282.98
Support 3 (S3) 281.38 286.13 282.35
Support 4 (S4) 280.44